BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kang MJ, Hong YS, Kim KP, Kim SY, Baek JY, Ryu MH, Lee JL, Chang HM, Kim MJ, Chang HJ. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Invest New Drugs. 2012;30:1607-1613. [PMID: 21706149 DOI: 10.1007/s10637-011-9703-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Goffin JR, Zbuk K. Epidermal growth factor receptor: pathway, therapies, and pipeline. Clin Ther 2013;35:1282-303. [PMID: 24054705 DOI: 10.1016/j.clinthera.2013.08.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
2 Hagan S, Orr MC, Doyle B. Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J 2013;4:3. [PMID: 23356214 DOI: 10.1186/1878-5085-4-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 4.7] [Reference Citation Analysis]
3 Jensen BV, Schou JV, Yilmaz M, Johannesen HH, Skougaard K, Linnemann D, Hogdall EV, Larsen FO, Johansen JS, Pfeiffer P, Nielsen DL. Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. Int J Cancer 2020. [PMID: 33336394 DOI: 10.1002/ijc.33448] [Reference Citation Analysis]
4 Brodowicz T, Ciuleanu T, Radosavljevic D, Shacham-shmueli E, Vrbanec D, Plate S, Mrsic-krmpotic Z, Dank M, Purkalne G, Messinger D, Zielinski C. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study. Annals of Oncology 2013;24:1769-77. [DOI: 10.1093/annonc/mdt116] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
5 Su J, Lai J, Yang R, Xu B, Zhu Y, Zhao M, Yang C, Liang G. Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women. BMC Gastroenterol 2019;19:17. [PMID: 30683047 DOI: 10.1186/s12876-018-0916-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
6 Temraz S, Mukherji D, Alameddine R, Shamseddine A. Methods of overcoming treatment resistance in colorectal cancer. Crit Rev Oncol Hematol 2014;89:217-30. [PMID: 24075059 DOI: 10.1016/j.critrevonc.2013.08.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
7 de Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J, de Gramont A, Hamilton SR. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol 2015;12:197-212. [PMID: 25421275 DOI: 10.1038/nrclinonc.2014.202] [Cited by in Crossref: 126] [Cited by in F6Publishing: 98] [Article Influence: 15.8] [Reference Citation Analysis]
8 Cheng L, Ren W, Xie L, Li M, Liu J, Hu J, Liu BR, Qian XP. Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories. Cancer Chemother Pharmacol 2014;74:1-13. [PMID: 24916545 DOI: 10.1007/s00280-014-2489-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
9 Silvestri A, Pin E, Huijbers A, Pellicani R, Parasido EM, Pierobon M, Petricoin E, Liotta L, Belluco C. Individualized therapy for metastatic colorectal cancer. J Intern Med 2013;274:1-24. [PMID: 23527888 DOI: 10.1111/joim.12070] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
10 Sotelo Lezama MJ, Sastre Valera J, Díaz-Rubio García E. Impact of cetuximab in current treatment of metastatic colorectal cancer. Expert Opin Biol Ther 2014;14:387-99. [PMID: 24479733 DOI: 10.1517/14712598.2014.883376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Kim TW. EGFR status is not a reliable biomarker to select patients suitable for cetuximab-based therapy. Clin Colorectal Cancer 2014;13:3-4. [PMID: 24373734 DOI: 10.1016/j.clcc.2013.11.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
12 Akhtar R, Chandel S, Sarotra P, Medhi B. Current status of pharmacological treatment of colorectal cancer. World J Gastrointest Oncol 2014; 6(6): 177-183 [PMID: 24936228 DOI: 10.4251/wjgo.v6.i6.177] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
13 Nagata N, Maeda H, Ishibashi K, Hirata K, Makiyama A, Iwamoto S, Takemoto H, Imasato M, Yoshida Y, Munemoto Y, Tanaka C, Morita Y, Hotta Y, Toyofuku A, Nagasaka T, Morita S, Sakamoto J, Mishima H. Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study). Med Oncol 2019;36:46. [PMID: 31020480 DOI: 10.1007/s12032-019-1254-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Jahanafrooz Z, Mosafer J, Akbari M, Hashemzaei M, Mokhtarzadeh A, Baradaran B. Colon cancer therapy by focusing on colon cancer stem cells and their tumor microenvironment. J Cell Physiol 2020;235:4153-66. [PMID: 31647128 DOI: 10.1002/jcp.29337] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
15 Wu SG, Chen XT, Zhang WW, Sun JY, Li FY, He ZY, Pei XQ, Lin Q. Survival in signet ring cell carcinoma varies based on primary tumor location: a Surveillance, Epidemiology, and End Results database analysis. Expert Rev Gastroenterol Hepatol. 2018;12:209-214. [PMID: 29227748 DOI: 10.1080/17474124.2018.1416291] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
16 Kamel HFM, Al-Amodi HSAB. Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine. Genomics Proteomics Bioinformatics 2017;15:220-35. [PMID: 28813639 DOI: 10.1016/j.gpb.2016.11.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 8.6] [Reference Citation Analysis]
17 Rosa B, de Jesus JP, de Mello EL, Cesar D, Correia MM. Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis. Ecancermedicalscience 2015;9:582. [PMID: 26557880 DOI: 10.3332/ecancer.2015.582] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
18 Hong YS, Kim HJ, Park SJ, Kim KP, Lee JL, Park JH, Kim JH, Lim SB, Yu CS, Kim JC, Baek JY, Kim SY, Kim TW. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. Cancer Sci 2013;104:473-80. [PMID: 23298313 DOI: 10.1111/cas.12098] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]